Marshall Wace
MRVI icon

Marshall Wace’s Maravai LifeSciences MRVI Stock Holding History

Marshall Wace’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.18M Sell
1,471,477
-609,857
-29% -$2.63M 0.01% 1075
2026
Q1 		$5.89M Buy
2,081,334
+81,056
+4% +$275K 0.01% 1222
2025
Q4 		$6.5M Buy
2,000,278
+687,253
+52% +$2.31M 0.01% 1037
2025
Q3 		$3.77M Buy
1,313,025
+990,915
+308% +$2.53M ﹤0.01% 1314
2025
Q2 		$776K Sell
322,110
-71,902
-18% -$151K ﹤0.01% 1957
2025
Q1 		$871K Sell
394,012
-2,384,485
-86% -$9.42M ﹤0.01% 1849
2024
Q4 		$15.1M Buy
2,778,497
+2,763,072
+17,913% +$17.8M 0.02% 641
2024
Q3 		$128K Sell
15,425
-3,989,459
-100% -$34.5M ﹤0.01% 2347
2024
Q2 		$28.7M Sell
4,004,884
-824,862
-17% -$7.12M 0.04% 391
2024
Q1 		$41.9M Buy
4,829,746
+2,182,413
+82% +$14.8M 0.06% 295
2023
Q4 		$17.3M Buy
2,647,333
+1,889,796
+249% +$12.2M 0.03% 519
2023
Q3 		$7.58M Buy
757,537
+703,612
+1,305% +$7.73M 0.02% 736
2023
Q2 		$670K Sell
53,925
-1,699,014
-97% -$22.9M ﹤0.01% 1877
2023
Q1 		$24.6M Sell
1,752,939
-987,757
-36% -$14.2M 0.05% 394
2022
Q4 		$39.2M Buy
2,740,696
+663,660
+32% +$10.4M 0.09% 250
2022
Q3 		$53M Buy
2,077,036
+1,538,680
+286% +$38.6M 0.12% 179
2022
Q2 		$15.3M Buy
538,356
+37,144
+7% +$1.18M 0.03% 608
2022
Q1 		$17.7M Buy
501,212
+106,404
+27% +$3.57M 0.03% 548
2021
Q4 		$16.5M Sell
394,808
-1,093,208
-73% -$44.3M 0.03% 573
2021
Q3 		$73M Buy
1,488,016
+1,414,052
+1,912% +$69M 0.3% 47
2021
Q2 		$3.09M Sell
73,964
-163,221
-69% -$6.33M 0.01% 1128
2021
Q1 		$8.45M Sell
237,185
-125,795
-35% -$4.17M 0.04% 544
2020
Q4 		$10.2M Buy
+362,980
New +$10.1M 0.06% 344

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Marshall Wace's MRVI Position: Q2 2026 in Review

Marshall Wace reduced its Maravai LifeSciences (MRVI) stake by 29% in Q2 2026, selling an estimated $2.63M and leaving 1,471,477 shares worth $9.18M. The position accounts for 0.01% of the portfolio, ranked #1075.

Marshall Wace first reported a position in MRVI in Q4 2020 and has held it in 23 quarters since. The position peaked at $73M in Q3 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Marshall Wace held 1,471,477 shares of Maravai LifeSciences worth $9.18M as of Q2 2026.
  • Marshall Wace sold 609,857 Maravai LifeSciences shares in Q2 2026, an estimated $2.63M.
  • Maravai LifeSciences made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #1075 holding.
  • Marshall Wace first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 23 quarters since.
  • Marshall Wace's Maravai LifeSciences position peaked at $73M in Q3 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.